Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Subretinal pseudocyst: A novel optical coherence tomography finding in age-related macular degeneration.

Sacconi R, Mullins RF, Lutty GA, Borrelli E, Bandello F, Querques G.

Eur J Ophthalmol. 2019 Apr 25:1120672119846437. doi: 10.1177/1120672119846437. [Epub ahead of print]

PMID:
31018677
2.

Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.

Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K.

Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2089-2096. doi: 10.1007/s00417-018-4121-7. Epub 2018 Sep 1.

PMID:
30173338
3.
5.

Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.

Shah VP, Shah SA, Mrejen S, Freund KB.

Retina. 2014 Jul;34(7):1281-8. doi: 10.1097/IAE.0000000000000166.

PMID:
24695062
6.

REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Dolz-Marco R, Phasukkijwatana N, Sarraf D, Freund KB.

Retina. 2017 Feb;37(2):222-233. doi: 10.1097/IAE.0000000000001279.

PMID:
27627752
7.
8.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

10.

INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.

Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.

Retina. 2016 Apr;36(4):770-7. doi: 10.1097/IAE.0000000000000751.

PMID:
26398691
11.

A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.

Park DH, Sun HJ, Lee SJ.

Int Ophthalmol. 2017 Oct;37(5):1205-1214. doi: 10.1007/s10792-016-0391-4. Epub 2016 Nov 8.

PMID:
27826933
12.

Aflibercept for neovascular age-related macular degeneration.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD.

Cochrane Database Syst Rev. 2016 Feb 8;2:CD011346. doi: 10.1002/14651858.CD011346.pub2. Review.

13.

REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.

Gianniou C, Dirani A, Jang L, Mantel I.

Retina. 2015 Jun;35(6):1195-201. doi: 10.1097/IAE.0000000000000465.

PMID:
25650710
14.

The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.

Abri Aghdam K, Seidensticker F, Pielen A, Framme C, Junker B.

Lasers Surg Med. 2016 Sep;48(7):668-77. doi: 10.1002/lsm.22531. Epub 2016 Apr 25.

PMID:
27111455
15.

IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.

Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH.

Retina. 2016 Jul;36(7):1331-9. doi: 10.1097/IAE.0000000000000902.

PMID:
26655608
16.

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.

Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.

PMID:
23706500
17.

Early detection of choroidal neovascularization facilitated with a home monitoring program in age-related macular degeneration.

Chaikitmongkol V, Bressler NM, Bressler SB.

Retin Cases Brief Rep. 2015 Winter;9(1):33-7. doi: 10.1097/ICB.0000000000000085.

PMID:
25383857
18.

Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.

Clemens CR, Wolf A, Alten F, Milojcic C, Heiduschka P, Eter N.

Acta Ophthalmol. 2017 Nov;95(7):683-689. doi: 10.1111/aos.13359. Epub 2017 Jan 13.

19.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9.

20.

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.

Cuesta-Lasso M, Vieira-Barros A, Dolz-Marco R, Roig-Revert MJ, Badal J, Amselem L, Díaz-Llopis M, Gallego-Pinazo R.

Arch Soc Esp Oftalmol. 2017 Mar;92(3):101-106. doi: 10.1016/j.oftal.2016.10.006. Epub 2016 Nov 29. English, Spanish.

PMID:
27912913

Supplemental Content

Support Center